Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2017 · 10-Q
Revenue—
Net Income$1.86M$1.86MN/M vs Q2 2016 EPS Diluted$0.01$0.01N/M vs Q2 2016 Operating Income-$2,177,789N/M Operating Cash Flowderived-$913,647N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
ended Jun 30, 2017 · filed Aug 10, 2017 · 41 d after period end